Lecture Notes By Dr. Myatt
The text that follows is a transcript of the lecture notes for a lecture presented by Dr. Myatt in May of 2000 at the 2000 Pacific Northwest Herbal Symposium where Dr. Myatt was a featured lecturer speaking on several subjects. It is reproduced here in it’s entirety including annotations and references (as is expected of any lecture presented to a medical or scientific body) so that readers may verify the information for themselves and engage in further research. We hope that this will be information useful to persons with an interest in this disease.
Botanical and Nutritional Considerations in the Treatment of
Dana Myatt, N.M.D.
Prostate carcinoma is a hormone-dependent cancer. Therefore, in addition to general immune enhancing and anti-cancer therapies, hormonal manipulation has a role to play in treatment of this disease.
Prostate carcinoma is the most common male cancer in the U.S. It accounts for an estimated 32% of all newly diagnosed cancers. (Other forms of prostate cancer, such as sarcoma, are rare and are not hormone-dependent). The incidence of disease increases with each decade of life over age 50. (1) Prostate cancer rates have risen 108% since 1950, believed due in part to earlier detection. Death rates from this disease have increased 23%.
There is great debate in the medical community regarding the value of conventional treatment. Prostate cancer is, in most cases, slow-growing. Increased survival rates reported in some studies may be due to earlier detection, not treatment. Many newly diagnosed and early stage cancers in older men would never progress to morbidity or mortality. Considering the risk of impotence (50-60% with surgery), incontinence (from surgery or radiation) and other treatment side-effects, the value of conventional therapy must be questioned in all cases of cancer in older men.
Botanical and nutritional treatment for cancer can be considered an adjuvant therapy in all cases of prostate carcinoma and the sole therapy in many. Even when conventional treatment is deemed advisable, non-traditional uses of conventional drugs may be safer and more advantageous than standard therapy. This is because, in it’s early stages, prostate cancer is highly controllable with hormone-blocking therapy.
Laboratory Evaluation of
In additional to generalized immune testing and basic cancer workup (chemistry screen, CBC, TFT’s, etc.), several tests specific to prostate disease allow the clinician to track progression non-invasively and with greater accuracy. These tests include prostatic-specific antigen (PSA), free PSA, prostatic acid phosphatase (PAP), and prolactin.
PSA is now used as the preferred screening test for both benign prostatic hypertrophy (BPH) and prostate cancer. Because PSA may be elevated in both benign and cancerous prostate disease, the test is not specific for prostate cancer. Values in the “indeterminate” range (4-12) present a special diagnostic dilemma. It is further estimated that 25% of men with prostate cancer will have PSA’s less than 4. Taken together, the PSA test poses a significant number of both false-negative and false-positive results. The PSA is an accurate measure of cancer cell activity once the diagnosis has been established.
Free-PSA is a more recent marker that has not yet been universally embraced by conventional medicine. Current research suggests that the free-PSA is a useful “next step” for evaluating elevated PSA’s. In men with PSA’s ranging from 4.1-10, higher levels of free-PSA (18.9 median value) correlated with benign disease while lower levels of free-PSA (10.1 median) correlated with cancer. It is estimated that 95% of “indeterminate” PSA readings could be clarified non-invasively with the additional use of the free-PSA test. (3)
Prostatic acid phosphatase (PAP) was the prostate cancer screening test that preceded use of the PSA. An elevated PAP in a patient with known prostate cancer is indicative of lymphatic spread of the disease. (4)
Prolactin hormone is an additional growth factor to the prostate gland, and rising prolactin levels correlate with progression in advanced prostate cancer cases. Prolactin receptors are found on prostate cancer cells, and it is postulated that these receptors may facilitate the entry of testosterone into the cell. Even with hormone ablation therapy, detectable androgen remains in the blood from adrenal sources. Blocking prolactin secretion may there fore be another method for slowing progression of the disease. It is recommended that prolactin levels be kept below 3 in all patients with hormone-responsive cancers. (5)
Specific Goals of Therapy
Testosterone, prolactin, cortisol, insulin, and arachidonic acid-derived prostaglandins (especially PGE2) act as growth factors for prostate cancer. Cyclooxygenase is the enzyme that catalyzes the conversion of arachidonic acid to prostaglandins. Decreasing circulating levels of these hormones and blocking inflammatory pathways should be undertaken in addition to non-specific cancer therapies such as immune enhancement.
1.) Beers, Mark M.D., Berkow, Robert M.D. , editors, The Merck Manual of Diagnosis and Therapy, Merck research Laboratories, 1999, p. 1918.
2.) Boik, John, Cancer and Natural Medicine, Oregon Medical Press, 1996, p. 87
3.) Faloon, William, Disease Prevention and Treatment Protocols, Life Extension foundation, Hollywood, FL, 1998, p. 192.
4.) Murphy, Gerald M.D., Lawrence, Walter Jr. M.D., Lenhard, Raymond M.D., Clinical Oncology, American Cancer Society, Atlanta, 1995, p. 315. [copies of this textbook may be obtained by calling your local branch of the American Cancer Society or call 1-800-ACS-2345].
5.) European Journal of Cancer, Vol 31A, No. 6, 1995.
Materia Medica classified by action
Reduce sex hormone bioavailability
Glycine max -soy
Linum ussatatissimum -flax
Arctium lappa -burdock
low dietary saturated fat
high dietary fiber
Cannabis sativa- marijuana
Serenoa Spp.- Saw palmetto
Rx: Casodex, flutamide, Lupron, Zoladex
Rx: Bromocriptine, Pergolide, Dostinex
Botanical Materia Medica
Arctium lappa (Compositae)- Burdock
Burdock reduces sex hormone bioavailability, perhaps due to its lignan content.(1) In vitro, it induces differentiation and inhibits tumor cell proliferation. (2) Burdock is considered highly in both Western and Chinese medicine as a detoxifier and it is an ingredient in the Hoxey formula. it is thought to stimulate the removal of excess metabolic acids. (3)
Linum ussitatissimum (Linacea)- Linseed, flax seed
Flax seed is much higher in lignans than other plants. Lignans inhibit sex hormone availability. Antiinflammatory effects are attributed to the high omega-3 fatty acid content of the seed oil.
Glycine max (Leguminosae)-Soy
Soy beans contain protease inhibitors, fixed oils, coumestrol, isoflavones including daidzein and genistein, lecithin, protein, vitamins and minerals. Soy foods reduce hormone bioavailability and cholesterol levels through several possible mechanisms, including weak estrogenic effects of the phytoestrogenic isoflavones and fiber content. Genistein is cytotoxic, induces apoptosis and differentiation, inhibits angiogenesis and metastasis (4), and blocks protein kinase which is a cancer growth factor (11) . The isoflavones in soy are both antioxidant and antimutagenic.(5)
One study of 8,000 Japanese living in Hawaii found that men who had the highest intake of soy had the lowest incidence of prostate cancer. Soy-eaters diagnosed with prostate cancer nevertheless have the lowest death rate in the world from the disease.(6)
Cannabis sativa (Cannabinaceae)- Marijuana
Marijuana contains flavonoids, volatile oils, alkaloids and over 60 different cannabinoids including THC.(7) Smoking the herb reduced testosterone levels or inhibited testosterone receptors in both animals and humans. It is known that marijuana smoking decreases male fertility. (8,9,10)
Serenoa repens, S. serrulata (Palmaceae)- Saw palmetto
Saw palmetto blocks the conversion of testosterone to dihydrotestosterone (DHT) (11) and there is evidence that DHT may be five times as potent as testosterone in stimulating prostate cancer cell growth. (12)
Vitex agnus-castus, V. negundo (Verbenaceae)- Chaste berry
Vitex spp. decreases testosterone production in vivo (13) and inhibits prolactin synthesis and release in animal models (14). As the name “chaste tree” implies, this herb was traditionally used by monks to reduce libido.
PC-SPEC is a new and novel Chinese herb formula used in the treatment of prostate cancer. “Spec” is Latin for hope, and the formula is reported to be effective in extending quality and length of life even in advanced, hormone-refractory cancers. The formula is cytostatic and cytotoxic, and regulates apoptosis (1). It may stimulate T4 (helper) cells and macrophages (2) and lower PSA levels (3). The popularity of the formula was enhanced by a recent mention in the New England Journal of Medicine which reported that:
“We found PC-Spec…. has potent estrogenic activity in yeast, mice, and humans. In patients with prostate cancer, it causes clinically significant reductions in serum testosterone concentrations, decreases PSA, and with side effects similar to those of pharmacologic doses of estrogen….. PC-SPEC may prove useful in the treatment of hormonally sensitive prostate cancer…..”(3).
The formula contains herbs which may address prostate cancer on a number of levels. According to the book New Guidelines for Surviving (4), the herbs and actions of PC-SPEC include:
1.) Isatis indigotica (da qing ye) contains beta sitosterol, a phytosterol which lowers the bioavailability of estrogen and reduces tumor yield in animals.
2.) Glycyrrhiza spp. (gan cao) stimulates the immune system and possesses in vitro antitumor activity. It also helps lower testosterone levels.
3.) Panax pseudo-ginseng (san qi) stimulates NK cell activity.
4.) Ganoderma lucidum (ling zi) contain polysaccharides that inhibit cancer cells and extend the lifespan of test animal with lung cancer up to 195%.
5.) Scutellaria baicalensis (huang qin) promotes apoptosis, stimulates the immune system and inhibits tumor-cell proliferation.
6.) Dendranthema morifolium Tzvel (Chu-hua) is a lesser-known Chinese herb with reported antiviral and detoxifying properties.
7.) Rabdosia rubescens (don ling cau) is a pain-relieving herb with multiple antitumor effects. Increased survival rates have been noted in patients with esophageal cancer.
8.) Serenoa repens or S. serrulata (Saw palmetto) decreases the bioavailability of testosterone and is widely used in the treatment of BPH.
The recommended dose is 6-12 capsules per day depending on the stage of the disease. This puts the cost of the formula at $300-$600 per month. (CHT averages $800 per month to give some perspective). Since the formula is a non-FDA approved herbal combination, it is available without a prescription.
Dr. Myatt’s comment: This formula has gotten a lot of good press lately. I’d like to see if the results will meet the hype. Unfortunately, since the formula is a non-FDA approved herbal remedy, I have found it challenging to get patients to take it with consistency in the doses recommended. I have yet to see results in two patients who have used it with regularity. PC-SPEC may indeed represent a breakthrough in the treatment of cancer. It could also be that some herbal product manufacturers are getting as clever as the drug companies in creating “buzz,” and getting journal space, about new products. How many “breakthrough” drugs have come and gone? Let’s hope PC-SPEC fares better than the current conventional treatments for prostate cancer.
1.) Halicka HD et al.: Apoptosis and cell cycle effects induced by extracts of the Chinese herbal preparation PC-SPEC. Intl J Oncology, 1997;11:437-448.
2.) Whittaker J: The Art of Alternative Medicine. ACAM Conference Proceedings Notes, Nov. 1998.
3.) DiPaola RS et al.: Clinical and biologic activity of an estrogenic herbal combination (PC-SPEC) in prostate cancer. New Engl J Med, Sept. 17, 1998;339(12);785-791.
4.) Lewis, James Jr.: New Guidelines for Surviving , Westbury, NY: Health Education Library Publisher, 1998.
Nutritional Materia Medica
Vitamin D3 (cholecalciferol)
Vitamin D3 induces prostate cancer cell apoptosis by apparent translocation of the cancer cell androgen receptor. This makes the cell less susceptible to testosterone-induced proliferation (15). D3 induces differentiation, inhibits angiogenesis and shows antitumor activity. It may also upregulate vitamin A receptors. (16)
Because vitamin D has the potential to cause toxicity, doses over 1,000mg should be carefully monitored. Increased blood calcium levels can result from toxicity. In clinical practice, D3 appears to benefit metastatic bone disease in higher doses, perhaps because this vitamin is needed for normal calcification of bone matrix.
Food sources of vitamin D include cold water fish (salmon, mackerel, herring), butter, egg yolks and dark green leafy vegetables. Sunlight acting on the skin will also create vitamin D. In areas of decrease sunlight, increases of breast and colon cancer have been observed. (17)
Melatonin is a hormone produced by the pituitary gland. It regulates circadian rhythms and plays a role in sleep regulation. It is also a more potent antioxidant than glutathione or vitamin E (19). In vitro, melatonin demonstrates antiestrogen activity and immune stimulation (18). Recent research shows that melatonin inhibits cell proliferation profoundly in vivo but only weakly in vitro. It is synergistic with IL-2 and increases the effectiveness of IL-2 treatment. (20)
CoQ10 is a vitamin-like substance that is involved in mitochondrial energy production. The heart is a high user of CoQ10, and many chemotherapeutic drugs deplete body stores of this nutrient. CoQ10 has been used successfully to reduce chemotherapy-induced cardiotoxicity.
In breast cancer patients, a dose of 90mg daily increase late-stage survival dramatically. Three cases of complete remission have been documented at higher doses (300-400mg) per day. (21)
Enzymes (multi enzymes)
Digestive enzymes, whether from animal sources (pancreatin, etc.) or botanical (bromelain, papain), have been shown to increase survival time, inhibit metastasis, and stimulate immune cells. Enzymes induce differentiation and inhibit angiogenesis (22), possibly through antifibrinolytic mechanisms. It has also been postulated that enzymes may help unmask tumor cells and make them more accessible to the immune system.
Low saturated fat diets decrease the body’s endogenous and exogenous hormone production. Conversely, diets high in saturated fats decrease NK cell activity and increase arachidonic acid, an inflammatory precursor. Rates of breast, colon, prostate, uterine, ovarian and testicular cancers are significantly higher in countries with high saturated fat intakes.
Saturated fats promote inflammatory prostaglandin synthesis while omega-3 fatty acids are antiinflammatory.
Low carbohydrate diets decrease the availability of glucose and insulin. Insulin is a growth factor for cancer and the primary metabolic pathway of cancer cells is anaerobic glycolysis, meaning that cancer cells thrive with a high glucose environment. In animal studies, even slight change toward metabolic acidosis resulted in tumor regression. A low carbohydrate diet which induces ketosis (metabolic acidosis) may duplicate this effect. Overweight patients can afford to lose weight on such a diet, to further reduce their endogenous hormone production. (Fat cells manufacture estrogen).
Foods of Special Benefit
lemon zest (the peel contains limonene)
soy and soy products
fresh vegetables (especially non-starchy, dark leafy greens)
blueberries and other berries (high in flavonoids and low in sugars)
grains (whole grain only, to reduce insulin response and increase fiber content. Grains should be used sparingly. In patients with more than twenty pounds to lose, gains need not be used at all until desired weight is achieved)
Materia Medica References
1.) Boik, John: Cancer and Natural Medicine, Oregon Medical Press, 1995, p. 159
2.) Ibid., p. 177
3.) Tilgner, Sharol N.D.: Medicines from the Earth, Wise Acres Press, 1999, p. 44.
4.) Ibid, Boik, p. 184.
5.) Editors of time-Life Books: The Drug and Natural Medicine Advisor, time-Life Books, Alexandria, VA. 1997, p.704.
6.) Yeager, Selene, editor: Food Remedies., Prevention Health Books, Rodale Press, 1998, p. 494.
7.) Chevallier, Andrew: Encyclopedia of Medicinal Plants. DK Publishing, London, 1996, p.180.
8.) Barnett G.,Chaing CW, Licko V: Effects of Marijuana on testosterone in male subjects. J Theor Biol 1983 Oct 21; …104(4):685-92
9.) Fujimoto GI, Morrill GA, O’Connell ME, Kostello AB: Effects of cannabinoids given orally and reduced appetite on the male rat reproductive system. Pharmagology 1982;24(5):303-13.
10.) Purohoit V, Ahluwahlia BS, Vigersky RA: Marijuana inhibits dihydrotestosterone binding to the androgen receptor. Endocrinology, 1980 Sep; 107(3):848-50.
11.) Sultan C, Terraza A, Devillier C, Carilla E, et al.: Inhibition of androgen metabolism and binding by a liposteric extract of Serenoa repens B in human forskin fibroblasts. J Steroid Biochem 1984 Jan; 20(1):515-9.
12.) The effects of Flutamide on total DHT and nuclear DHT levles in the human prostate. Prostate, 1981, 2/3: 309-314.
13.) Bhargava SK: Antiandrogenic effects of a flavonoid-rich fraction of Vitex negundo seeds: a histological and biochemical study in dogs. J Ethnopharmacol 1989 Dec; 27(3):327-39.
14.) Bohnert KJ: The use of Vitex agnus castus for Hyperprolactinemia. Quarterly Review of Nat Med Spring 1997;19-20.
15.) Vitamin D and : 1,25 Dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrin 1993;132(5):1952-60.
16.) Majewski S, Szmurlo A, Marczak M, Jablonska S, Bollag W: Inhibition of tumor-cell induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their combination. Canceer Lett 1993 Nov 30; 75(1):35-9.
17.) Murray M: Encyclopedia of Nutritional Supplements. Prima Publishing, 1996: p.40.
18.) reiter RJ, Melchiorri D, Swewerynek E, Poeggeler B, et al.: A review of the evidence supporting melatonin’s role as an antioxidant. J Pineal Res 1995; 57:125-28.
19.) Hill SM, Spriggs LL, Simon MA: The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett 1992 Jul 10;64(3):249-56.
20.) Lissoni P, Barni S, Cazzaniga M, et al.: Efficacy of the concommitant administration of the pineal hormone melatonin in cancer immunotherpay with low-dose IL-2 in patients with advanced solid tumors who had progressed on IL-2 therpay alone. Oncology 1994b Jul-Aug; 51(4):344-7.
21.) Boik, John: Cancer and Natural Medicine, Oregon Medical Press, 1995, p. 71.
22.) 22.) Ibid., p.184.